Strategies that optimize the treatment decision-making paradigm for individuals with human epidermal growth factor 2 (HER2)-positive early breast cancer are imperative, as we move further into an era of highly effective novel therapies and multi-agent regimens. This evidence concerns the gene ERBB2 and breast carcinoma.